vaccination

In this article the authors conducted a study involving adults (≥50 years of age) with COVID-19–like illness who underwent molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

In this article the authors extracted data for the period from July 30 through August 31, 2021, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (i.e., had received two doses of BNT162b2) at least 5 months earlier.

In this article the authors aimed to uncover if headache patients develop more headaches after COVID-19 mRNA vaccination than healthy controls.

In this review, the authors discuss contemporary methodologies employed to investigate possible associations between vaccination and adverse neurological outcomes and why determining causality can be challenging.

This review aims to provide a clinical practice-oriented approach to SARS-CoV-2 vaccination in MS in the era of the COVID-19 pandemic.

In this article, the authors provide a snapshot of ongoing vaccine efficacy studies, as well as real-world data on vaccine effectiveness and the impact of virus variants of concern.

The authors analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020.

The objective of this prospective cohort study was to determine associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with COVID-19 among nursing home residents, nursing home staff, and healthcare workers.

The objective of this test negative design study was to estimate the effectiveness of mRNA COVID-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).

The authors of this study report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.

For this multicentre cohort study, clinicians were asked to submit all cases in which COVID-19 vaccination preceded the onset of cerebral venous thrombosis, regardless of the type of vaccine, interval between vaccine and onset of cerebral venous thrombosis symptoms, or blood test results.

Cross-sectional case-control studies (Blue) Bell’s palsy is a rare adverse event reported in clinical trials of COVID-19 vaccines. However, no population-based study has assessed the association between the inactivated SARS-CoV-2 vaccines and Bell’s palsy. The aim of this study was… Continue Reading

In this article the authors describe two patients who developed sensory Guillain-Barre syndrome (GBS) shortly after the first dose of the ChAdOx1 vaccine.

This study investigated the vaccine hesitancy and coping styles in patients with NMOSD to analyze the relationship between vaccine hesitancy and coping styles, and elucidate the factors influencing vaccine hesitancy.

In this article the authors conducted a prospective cohort study involving patients with suspected VITT who presented to hospitals in the United Kingdom between March 22 and June 6, 2021.